Moderna, Inc. last reported quarterly results on Jul 31, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $145.0 million (+2.1% year over year) and diluted EPS of -$1.97. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Jul 31, 2026
31 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
145
+2.1%
|
-782
+5.2%
|
-1.97
+7.5%
|
|
May 1, 2026
31 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
389
+260.2%
|
-1,343
-38.3%
|
-3.40
-34.9%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
678
-29.8%
|
-826
+26.2%
|
-2.11
+27.2%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,016
-45.4%
|
-200
-1638.5%
|
-0.51
-1800.0%
|
|
Aug 1, 2025
32 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
142
-41.1%
|
-825
+35.5%
|
-2.13
+36.0%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
108
-35.3%
|
-971
+17.4%
|
-2.52
+17.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
966
-65.6%
|
-1,120
-616.1%
|
-2.89
-609.5%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1,862
+1.7%
|
13
+100.4%
|
0.03
+100.3%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MRNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1682852
- Former names
- Moderna Therapeutics, Inc. (until Aug 24, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.